Pathstone Holdings LLC Raises Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Pathstone Holdings LLC boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,381 shares of the company’s stock after buying an additional 1,231 shares during the quarter. Pathstone Holdings LLC owned approximately 0.08% of TransMedics Group worth $4,142,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vaughan Nelson Investment Management L.P. purchased a new position in TransMedics Group in the second quarter worth $39,862,000. Driehaus Capital Management LLC grew its holdings in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Principal Financial Group Inc. grew its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Hood River Capital Management LLC purchased a new position in TransMedics Group in the second quarter worth $18,854,000. Finally, Canada Pension Plan Investment Board purchased a new position in TransMedics Group in the second quarter worth $16,086,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock valued at $5,230,528 over the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TMDX shares. Piper Sandler cut their price target on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday. Oppenheimer lowered their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Stephens boosted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, Robert W. Baird cut their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Stock Down 4.2 %

TMDX stock opened at $76.04 on Friday. The stock has a market capitalization of $2.55 billion, a P/E ratio of 80.89 and a beta of 2.08. The firm has a 50-day simple moving average of $119.18 and a 200-day simple moving average of $137.70. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52 week low of $67.77 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. Equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.